Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors Journal Article


Authors: Ghadban, T.; Perez, D. R.; Vashist, Y. K.; Bockhorn, M.; Koenig, A. M.; El Gammal, A. T.; Izbicki, J. R.; Metzger, U.; Hauswirth, F.; Frosina, D.; Jungbluth, A. A.
Article Title: Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors
Abstract: Introduction: Expression of cancer testis antigens (CTAs) has been associated with prognosis in gastrointestinal stromal tumors (GIST) and other malignancies. CTAs are currently being investigated for cancer immunotherapy. Materials and methods: We analyzed two CTAs, CT10/MAGE-C2 and GAGE, in 51 GIST by immunohistochemistry and correlated it with established histopathological criteria for malignancy. Results: GAGE expression was found in 6/51 (12%) patients, whereas 5/51 (10%) patients expressed CT10/MAGE-C2. 7/51(14%) patients expressed at least one of both CTAs, in 4/51 (8%) patients both CTAs were positive. High-grade GIST are more likely to express GAGE (p = 0.002) and CT10/MAGE-C2 (p -= 0.007) compared to less aggressive tumors. All patients with GAGE or CT10/MAGE-C2 expression had moderate- or high-risk of recurrence according to the established risk criteria. The presence of GAGE correlates with mitotic rate (p = 0.001) and tumor size (p = 0.02), but not with tumor location (p = 0.60). CT10/MAGE-C2 also significantly correlates with mitotic rate (p = 0.004) and tumor size (p = 0.002), whereas no correlation could be found with tumor location (p = 0.36). Discussion: CT10/MAGE-C2 and GAGE should be explored together with other previously described CTAs as targets for immunotherapy of GIST in cases, which are refractory to conventional therapy. (C) 2014 Elsevier Ltd. All rights reserved.
Keywords: gastrointestinal stromal tumor; melanoma; pathology; diagnosis; cancer/testis antigens; trial; double-blind; immune-responses; phase-ii; ct10/mage-c2; adjuvant imatinib; gage; prognosis
Journal Title: European Journal of Surgical Oncology
Volume: 40
Issue: 10
ISSN: 0748-7983
Publisher: Elsevier Inc.  
Date Published: 2014-10-01
Start Page: 1307
End Page: 1312
Language: English
ACCESSION: WOS:000343380600020
DOI: 10.1016/j.ejso.2014.03.011
PROVIDER: wos
PUBMED: 24713551
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Achim Jungbluth
    454 Jungbluth
  2. Denise Frosina
    123 Frosina